Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Pfizer and BioNTech Announce -2-

09/20/2021 | 06:45am EDT
             (inflammation of the heart muscle); pericarditis (inflammation of 
             the lining outside the heart); injection site pain; tiredness; 
             headache; muscle pain; chills; joint pain; fever; injection site 
             swelling; injection site redness; nausea; feeling unwell; swollen 
             lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain 
 
   -- These may not be all the possible side effects of the vaccine. Serious 
      and unexpected side effects may occur. The vaccine is still being studied 
      in clinical trials. Call the vaccination provider or healthcare provider 
      about bothersome side effects or side effects that do not go away 

There is no information on the use of the vaccine with other vaccines.

Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit https://www.globenewswire.com/Tracker?data=xdypPuTxcjAtzMWzjupygR06KoCRJLFZaTYPSRomIdcIUtE6Jt_y5MhWgVwDX4Vk0zcgC_lHD-T47lptcHwKmwCQzXZJzqFrKx9JfmWmVrsBZbf9FTiFNoNhyBykvBsjZ77oraPEodzvNxfijM1uq-18TpeEaSOFz80WfRN3V4Sy41Hw3cqcgJjbpMNxjkyfkOzVFhrtig2d0Z0cX0APRCi3mVYfG0UCWhexvFVIFZO5YfotM-2nBB55JAiPjR4OgqiU_2yQD7SRg1y34QQjHQx3TVj3b8O3Vyc6RIZx8UNym8S8hb1F0ng4INOZgsDI http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at https://www.globenewswire.com/Tracker?data=DobgjF5UFLwybFyJOjveH4ANGz39pNLU9vo2bKYjFMRhqcUuHBKSxosuLoLGlJTDnqwx6KlOewlTSry9Brl0o-MxfLyi4ls26bY8iYVAQ05Np5f4wNax_W9r9VJh-zWNMU5CbOHv_M2-4Y9mq6xaKala-_Z5B2R0keCL8bIxfSqR_R-eU8xKrazdUw605wGb0VHFmJFw12znm2Yb-_EYH8hJdTZtMdfCI9aP631wtv7m5570rXWTP_q0N4Ho37_USInlg6lGoxXxhPPDF8LDGNH6p_zhPs4Nq4xlfiQy_NLVDIRik1lb8rjCwgMUW6wc2JAWm4ZeNFJmn2sKe1d7Bw== www.pfizersafetyreporting.com or by calling 1-800-438-1985.

Please https://www.globenewswire.com/Tracker?data=4AmawpC-6emOuGg_U5ohJo_0SlY_fFoxwxm8FP33z4LIesBQKeDSnDXeMb6qS7fQK4X39HsatK3yKvjhE4jItThVetvaKSH26hdeGkKNsdjJ4H2n3T9IDlbKJLQyo5CrAlwCttxf-TpXzN8l3-EXf89CmjYV7W1vIDepyT1o0Xa610_t9IPSZ4gc7546mAs8c5i_Qkhf5nHShttAHZYRWtBUeE0TG9ZGh1JIWSSIrArw_ljnskSewRIKjNgKTXwMZmwKQUhDQkq2LkX41SN28LVWh-ZWcVAyTFE55W_qSXjJwdzez6FntrqWkbET3ZmRpFhdic7alKERc-iKfqD4Pw== click here for full Prescribing Information (16+ years of age). Please https://www.globenewswire.com/Tracker?data=4AmawpC-6emOuGg_U5ohJrjpP762zjtIV1FSDYtJ2P-ia3gJI4ov06IE_MByy9m0l7zWR3rLhc0msi_Q_Y9fXyqNMzFOY2h1Tr7ubPCOZoQywEs8ooixYzQutWlVsp_PxRG3uK1sOSsIQvf5e_7GB0b7f1pEhj5PiUeItFrTGrKKA_HhZyyNWjgKhraCIWSprC3GGnajU33rQ66_VTOVbsYpX33FBrDKauJJGcFJ4ZeGQzd3ZvMY6f3Mcam3YHqksx8VLsXnQwPaXsl1ssCAgVX9up-dP3ugdIFEvReokMvSNc3jh-VdjzWpPFR6rAvv3chpW9FTRz698YsbJl_jeg== click here for Fact Sheet for Vaccination Providers (12+ years of age).

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at https://www.globenewswire.com/Tracker?data=DobgjF5UFLwybFyJOjveH7l_isO49y5ZxGVdd5pykx23qbQ_vR0NmDG0C7vs6LoAG3r6i12tamK2oZdVabalr-9F4u6AM6JgLkXJIG-j1WttplPz3xIqjk09c8l6uaPC-Xrl1utOwyk8I3hTs0Y1CzwhZfuD_ga4GU4EgMH6PuNp_7Pho0kKSt9QzIcT8kw2HUuZsbRHiQxsohunHGXT8obZf9fyixR-VKm6jsqrBElGccohiZLInyYNHRr8l7iOTiuiwDatTJFLwBELg16FrMQhgZXb258vyRv3O4Ai_4c= www.Pfizer.com. In addition, to learn more, please visit us on https://www.globenewswire.com/Tracker?data=DobgjF5UFLwybFyJOjveH_F-aI2fYhR9c0SZj5_narv48qhXKGmnfytJZrz9oQUvMyqucc8gLnWwLSXBoXBI5XdPHxIBjfexcQaESwJVIjJkr4X9bO4_bd_h99RF4xcax2uqbZrD8UDlQlPTWuKYW-bq1TWzRxskuHuDHVTMj_qipo_Vg44tQ0f-Gl8uaQJdb-NAnwsc8IPcb4CF72RXA24kW4iM1DCtVe9WkfHhAdFJYi_sYP0rU09_0EyWkCaEdIOcN4quq06JmI2wWBoP55V-4EeBMo4hx4uYadzjIaU= www.Pfizer.com and follow us on Twitter at https://www.globenewswire.com/Tracker?data=HmjwpONLv-_K-ZzsE2IXG-jsfhYNCZw4eiSJ1guzdDL4IZa_CnckhKGUxX15T2C7BqwWL1MRbeQLSRzier9UrlKIlTlxrxiMjlelM_XAchE19KurPe0qt4XTsWBCKQ3pqtiKAygxmWjReAQa_bzKD8vMXUKIYZ0rMuf2Loqb3PDazxFSB8o51td6h1Vh0ooP7qXDyvON2zi7VN5sLmX_SXLFII7E9OTv3FJ3yzjVFf3uHLuiPaeuZIAYXnW1E5p1i6JTG2Rq_yYhxJ4S6vzgvQ== @Pfizer and https://www.globenewswire.com/Tracker?data=HmjwpONLv-_K-ZzsE2IXG7nM7LuTQajyQD5hyN_U_v1t-U81rgAMAFtq2bRoDaHVmM6906UpIRLp9axoakXDVY9b0jXX7Wg8gQ9eyARvPEMMXyAgPm-QAanYLl2LHZMHzI4h-8kA0KVbzFqknCEfsAkx_E3L-uTfDbe2ZhqI0hLOjIpcLZV5XDFpEX3dBz4sW13Z0lo3Osw67gUHfzmEZgHeXgVW6FYmP2TBbyce3xuwVEItv7AehHOEaLFrGdcbJn8eKSrYeWaWhiMayxsM8lJE3sAK-uG2XSbZcSAm4Hc= @Pfizer News, https://www.globenewswire.com/Tracker?data=X8_frO7xai-ADFtCyMojnPbt0t65ppGwlAtpc_7tOKRZlQpV1veLd2lzLSCUWrcb67qoqrNw1bdN5xXTSxqcR7vQOZPDwrT1MldVGNh6fnyiCjfkdpOy2P0V-bGfc2tlfUgOr7SRvC0y_oG-_WN0Ht0oKh3qQehPMsk_FwEKO4s-R3PmoBlQc9Oy2XB9sE6PW2F7UlKwtFtZ5l-pg3Jtm06lxJFwYYbbNERQdOunjHcs9JTxYLAY0_C86DozUj2JGCjD3RL4vaGZtVazTmN12yBc6icd_RE4edlWLzc9nys= LinkedIn, https://www.globenewswire.com/Tracker?data=BZ6aOm6hcWVJyMx7m1RnL6XzwoeWFuCn4OvQejzJOForgSWkSQuhI8nOogkCaL8G1Ulkj71ul9xRO8m5HVQA-wTBrULTLS8jNceQSMV96VMJGVCjPI7NNkE_6z82L7KQ8ulZzY9ghZ924PMB27b4HRbQR-ifpdzDBqMHd2fqjIthzur2e7WeKPht49sZ7UWfCYkYbhQb8WXwpEkEyVim8algfFnxtY0clzWLTAbqeRN_rMftabXVyC388LrxSNVWMvRjOXQ_HubdYfE6lT7edCW28cUF-KIDLgpT6DzCAGA= YouTube and like us on Facebook at https://www.globenewswire.com/Tracker?data=8P9XoIgulyJvYsnMIDzHQROaKjhREWekIlZZLNU1rE5nM23FJrWFi6s_6X782Uyq07j9gBhz_wqe-RDaElAl9esZN4KNr6HDCpgb387HtVlDiOGQNyt2Mr5M9m4Ex_bt2JgI7xLJsLld7Kn1zaU5kWv-L6TEs4AaigMQwphlk-TnIppHOm_Y7mgizG6LInEvoyJv2NO9fnpTJPbgAsnlxL9CL_Zw5m5isFHyU413y2BjnGOKkuQWQioclBYaCulBGxuuX60lba_OM1eY6K8KYS3BhKsrV4Sm4Oak_Fj_NtZ_s6XCLZMYvYgVxPd9NsxN Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of September 20, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer's efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including the potential in children 5 to 11 years of age and a study in children 6 months to 5 years of age, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of data readouts, regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 2/3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when data from BNT162b2 in younger pediatric populations will be submitted to the FDA and other regulatory authorities to request amendments to emergency use or conditional marketing authorizations, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the potential amendments to request

(MORE TO FOLLOW) Dow Jones Newswires

September 20, 2021 06:45 ET (10:45 GMT)

All news about BIONTECH SE
12:03pEuropean ADRs Move Lower in Monday Trading
MT
11:28aModerna Shares Higher After Interim Data for Covid-19 Vaccine in Children
DJ
07:39aUNIVERSITY OF BIRMINGHAM : A third of leukaemia patients do not generate any antibody resp..
AQ
10/22Health Care Up On Defensive Bias -- Health Care Roundup
DJ
10/22MODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
RE
10/22Walmart, Walgreens U.S. stores roll out Moderna, J&J COVID-19 booster shots
RE
10/22PFIZER : FDA Panel to Vote on Pfizer COVID-19 Shots for Kids; Data Shows Vaccine 90.7% Eff..
MT
10/22European ADRs Move Higher in Friday Trading
MT
10/22PFIZER : Norway Stops Second Dose COVID-19 Vaccine Inoculations For Minors
MT
10/22PFIZER : BioNTech COVID-19 Vaccine Shows Nearly 91% Efficacy in Kids
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 16 703 M 19 377 M 19 377 M
Net income 2021 8 797 M 10 205 M 10 205 M
Net cash 2021 8 661 M 10 048 M 10 048 M
P/E ratio 2021 7,23x
Yield 2021 -
Capitalization 61 368 M 71 229 M 71 192 M
EV / Sales 2021 3,16x
EV / Sales 2022 2,54x
Nbr of Employees 2 500
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 254,09 €
Average target price 254,59 €
Spread / Average Target 0,20%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE261.78%67 225
GILEAD SCIENCES, INC.16.15%84 306
WUXI APPTEC CO., LTD.24.08%64 578
REGENERON PHARMACEUTICALS19.27%59 507
VERTEX PHARMACEUTICALS-21.73%47 610
BEIGENE, LTD.49.95%35 360